Search results
Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
- Patients & Caregivers
At Bristol Myers Squibb, we are committed to helping you get...
- Healthcare Providers
Bristol Myers Squibb provides information and resources to...
- Researchers
Bristol Myers Squibb wishes to advance science through...
- Investors
Forward-looking statements contained on this website should...
- Business Development
As a leading biopharma company, partnering is a key priority...
- News
Welcome to our newsroom - get access to information and...
- About Us
We promote health equity and seek to improve the health...
- Medicines
Bristol Myers Squibb focuses on developing new medicines to...
- Patients & Caregivers
Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.
We promote health equity and seek to improve the health outcomes of populations disproportionately affected by serious diseases. Learn about global biopharmaceutical innovator Bristol Myers Squibb, helping millions to fight cancer, cardiovascular disease, HIV/AIDS, and more.
Learn about the company's marketed products for various diseases and conditions, including ABECMA, BREYANZI, ELIQUIS, OPDIVO, and more. Find prescribing information, medication guides, and side effect reporting for each product.
At Bristol Myers Squibb, your work helps people prevail over serious diseases. From the scientists behind the microscope to the analysts behind the data, everyone at BMS is working to make an impact. And while our work transforms the lives of patients, it also transforms the lives and careers of our people.
6 days ago · The Food and Drug Administration approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more ...
3 days ago · Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two other ...